SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

BACKGROUND: HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like protein (SH3B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Li, Hui, Zhang, Mingming, Wei, Yanli, Haider, Farhan, Lin, Yitong, Guan, Wen, Liu, Yanbin, Zhang, Shaoyang, Yuan, Ronghua, Yang, Xia, Yang, Shulan, Wang, Haihe
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204297/
https://ncbi.nlm.nih.gov/pubmed/32381043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01577-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars